Leptin in hepatocellular carcinoma.
Wang SN, Lee KT, Ker CG.
SourceDivision of Hepatobiliary Surgery, Department of Surgery, Kaohsiung Medical University Hospital, 100 Tzyou 1st Road, San-Ming District, Kaohsiung 807, Taiwan, China. snwang@kmu.edu.tw
Abstract
The risk factors for hepatocellular carcinoma (HCC) development have been established, and include chronic hepatitis B and C, heavy alcohol consumption, and aflatoxins. In fact, 5%-30% of patients with HCC still lack a readily identifiable risk factor. It has been reported that the majority of 'cryptogenic' HCC may be attributed to nonalcoholic fatty liver disease, the hepatic presentation of the metabolic syndrome (MS). Obesity is associated with the development of the MS. Recently, adipose tissue has been considered as an endocrine organ because of its capacity to secrete a variety of cytokines, which are collectively known as the adipokines. Leptin, the product of the obese gene, is mainly produced by adipose tissue. Since leptin was first characterized in 1994, accumulated literature has demonstrated the involvement of this adipokine in several areas of human physiology. After binding to its receptor, leptin initiates a cascade of signaling events and subsequent cellular effects. In addition to being the regulatory mediator of energy homeostasis, several in vitro studies have demonstrated the fibrogenic role of leptin in the liver. Furthermore, the deregulated expression of leptin and its receptor have been demonstrated to be associated with a variety of metabolic disorders as well as human cancers. Most importantly, direct evidence supporting the inhibitory and/or activating role of leptin in the process of carcinogenesis and progression of human HCC has been accumulating rapidly. This review aims to provide important insights into the potential mechanisms of leptin in the development of HCC. Hopefully, further investigations will shed light on a new therapeutic target in HCC.
World J Gastroenterol 2010,Dec.14;16(46):5801-9
·
肝細(xì)胞癌中的Leptin
作者：北京經(jīng)緯博恒生物科技開發(fā)有限責(zé)任公司 2011-06-13T00:00 (訪問量:37469)
北京經(jīng)緯博恒生物科技開發(fā)有限責(zé)任公司 商家主頁
地 址： 北京市海淀區(qū)萬壽路街道太平路甲40號22樓411(軍醫(yī)科院南門).廊坊經(jīng)濟(jì)技術(shù)開發(fā)區(qū)翠微南道29號(生產(chǎn)基地)
聯(lián)系人： 李經(jīng)理
電 話： 業(yè)務(wù)：010-68167058，手機(jī):18210299625
傳 真： 010-68167058
Email：genwaybh@163.com
相關(guān)咨詢
肝細(xì)胞癌中的Leptin (2011-06-13T00:00 瀏覽數(shù):37469)
人和牛奶中的宿主防御蛋白 (2011-06-01T00:00 瀏覽數(shù):36903)
乳腺癌病人組織中LEPTIN水平 (2011-05-24T00:00 瀏覽數(shù):35588)
LEPTIN于膿毒癥中是一種危重病人適合的生物標(biāo)志嗎? (2011-05-20T00:00 瀏覽數(shù):37489)
乳鐵蛋白是II型糖尿病人患致死性心臟缺血的預(yù)警因子 (2011-05-16T00:00 瀏覽數(shù):35119)
血清乳鐵蛋白水平是一種過敏性鼻炎的診斷指標(biāo) (2011-05-11T00:00 瀏覽數(shù):76776)
Serum leptin: a marker of prostate cancer irrespective of obesity. (2011-05-10T00:00 瀏覽數(shù):30543)
LEPTIN 是一種住院老年病人營養(yǎng)評估的有效生物指標(biāo) (2011-05-09T00:00 瀏覽數(shù):33247)
Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis (2011-05-06T00:00 瀏覽數(shù):25186)
血清瘦素質(zhì)與心臟代謝危險(xiǎn)相關(guān) (2011-05-04T00:00 瀏覽數(shù):35052)
ADVERTISEMENT